Science Explorer Back to mapMap
Discussion
Topic · Pulmonary and Respiratory Medicine

Metastasis and carcinoma case studies

Metastasis and carcinoma case studies is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 24k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the metastatic behavior, clinicopathological characteristics, molecular profiling, and therapeutic targets of metastatic carcinomas, particularly from lung tumors and breast cancer. It explores the role of GATA3 as a prognostic marker, the use of immunohistochemistry in diagnosis, and the identification of potential therapeutic targets for these aggressive metastatic cancers.

  • Metastatic Carcinomas
  • Lung Tumors
  • Breast Cancer
  • GATA3
  • Sarcomatoid Carcinoma
  • Pleomorphic Carcinoma
  • Immunohistochemistry
  • Molecular Profiling
  • Therapeutic Targets
  • Prognostic Markers
Research works
24k
fractional, since 1950
In the world top 10%
2.5k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-7%
the tick is no change
Largest producer
China
29% of the 10 largest, 2022-now
Metastasis and carcinoma case studies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Metastasis and carcinoma case studies research?

By volume, China and the United States publish the most (911 and 739 works in 2022-now).

By volume, 2022-now

  1. 1 China 911 works
  2. 2 United States 739 works
  3. 3 Japan 596 works
  4. 4 India 206 works
  5. 5 Germany 127 works
  6. 6 South Korea 125 works
  7. 7 Italy 118 works
  8. 8 Türkiye 99 works
  9. 9 United Kingdom 95 works
  10. 10 Russia 87 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 29.4%United States: 23.8%Japan: 19.2%India: 6.6%6 others listed: 21.0%29%largest
China911 · 29.4%United States739 · 23.8%Japan596 · 19.2%India206 · 6.6%6 others listed651 · 21.0%

Shares of the rows listed above, not of the whole node.

Which institutions lead Metastasis and carcinoma case studies research?

By volume in 2022-now, Sichuan University publishes the most Metastasis and carcinoma case studies research, followed by Sun Yat-sen University and Chinese Academy of Medical Sciences & Peking Union Medical College.

By volume, 2022-now

  1. 1 Sichuan UniversityChina 31 works
  2. 2 Sun Yat-sen UniversityChina 31 works
  3. 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 26 works
  4. 4 Nanjing Medical UniversityChina 26 works
  5. 5 Shanghai Jiao Tong UniversityChina 24 works
  6. 6 The University of Texas MD Anderson Cancer CenterUnited States 24 works
  7. 7 Harvard UniversityUnited States 22 works
  8. 8 Zhejiang UniversityChina 20 works
  9. 9 All India Institute of Medical SciencesIndia 20 works
  10. 10 Peking UniversityChina 19 works

Who are the leading researchers in Metastasis and carcinoma case studies?

The most-cited researchers publishing on Metastasis and carcinoma case studies include Gad A. Getz, Matthew M. Meyerson and Reza Malekzadeh.

  1. 1 Gad A. Getz United States 364k citations
  2. 2 Matthew M. Meyerson United States 280k citations
  3. 3 Reza Malekzadeh Iran 278k citations
  4. 4 Gordon Brent Mills United States 265k citations
  5. 5 Charles M. Perou United States 263k citations
  6. 6 Carlo La Vecchia Italy 258k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Metastasis and carcinoma case studies?

The most cited paper in Metastasis and carcinoma case studies is "THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA" (P Laurén, 1965), with 6,205 citations. Next come "Two pathogenetic types of endometrial carcinoma" (2,528) and "Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition" (2,522).

Most cited papers
#PaperReleasedCitations
1 THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA P Laurén · Acta Pathologica Microbiologica Scandinavica Sep 1965 6,205
2 Two pathogenetic types of endometrial carcinoma Jan V. Bokhman · Gynecologic Oncology Feb 1983 2,528
3 Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition Min A Yu, Aditya Bardia, Ben S. Wittner et al. · Science Open access 31 Jan 2013 2,522
4 PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors Michael Charles Heinrich, Christopher L. Corless, Anette U. Duensing et al. · Science 30 Jan 2003 2,311
5 Metastases in carcinoma.Analysis of 1000 autopsied cases Herbert L. Abrams, Robert Spiro, Norman P. Goldstein · Cancer Open access 1950 1,873
All 100 most cited papers, with filters and sorting

Where is Metastasis and carcinoma case studies research done?

The largest centres of Metastasis and carcinoma case studies research in 2022-now are Tokyo (Japan), Beijing (China), Shanghai (China) and Seoul (South Korea).

Largest cities, 2022-now

  1. 1 TokyoJapan 123 works
  2. 2 BeijingChina 98 works
  3. 3 ShanghaiChina 75 works
  4. 4 SeoulSouth Korea 60 works
  5. 5 OsakaJapan 55 works
  6. 6 GuangzhouChina 54 works
  7. 7 MoscowRussia 48 works
  8. 8 ChengduChina 48 works
  9. 9 HangzhouChina 42 works
  10. 10 NanjingChina 42 works
See Metastasis and carcinoma case studies on the map

Where is the best place to study Metastasis and carcinoma case studies?

Among universities, judged by research, Harvard University, Sun Yat-sen University and Sichuan University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 18.54%fractional works in this field (log) →share of work in the world top 10% →Harvard UniversityUniversity of MiamiSun Yat-sen UniversitySichuan University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 73.327.1%2.0×22 -22.9%
2Sun Yat-sen UniversityChina 64.917.9%4.2×31 -17.9%
3Sichuan UniversityChina 56.78.6%3.9×31 +8.7%
4University of MiamiUnited States 54.524.0%4.3×9 +59.5%
5Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 53.615.2%7.2×26 -18.8%
6Seoul National UniversitySouth Korea 51.417.9%3.2×13 -17.0%
7Università Cattolica del Sacro CuoreItaly 51.418.1%5.8×9 +62.9%
8Sungkyunkwan UniversitySouth Korea 50.625.4%4.0×10 -36.2%
9Nanjing Medical UniversityChina 49.311.1%8.3×26 -10.1%
10Johns Hopkins UniversityUnited States 48.920.1%1.6×8 +6.8%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Metastasis and carcinoma case studies, country by country

Is Metastasis and carcinoma case studies research growing?

Output in 2022-2025 was 7% lower than in 2018-2021, peaking in 2019.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Metastasis and carcinoma case studies as a percentage of every work published that year, 0.017% in 2024.

still counting0.020%0.040%Metastasis and carcinoma case studies0.015% in 202519801990200020102020

Fractional works of Metastasis and carcinoma case studies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Metastasis and carcinoma case studies10.3% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Metastasis and carcinoma case studies. Posts are plain text and can be reported.